KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Kuzey Klinikleri / 2022 / Cilt: 9 - Sayı: 3

Escitalopram co-prescription in anastrozole-treated breast cancer patients

Hasan ÖZYURT
Sevgi ÖZDEN
Cengiz GEMİCİ
Pınar ÜLER
Gökhan YAPRAK
Hüseyin TEPETAM
Esra KÜÇÜKİBRAHİMOĞLU
Mehmet Zafer GÖREN
Hatice ODABAŞ
Neşet NEŞETOĞLU
Durisehvar URAL
Mahmut GÜMÜŞ
Sayfa
248–255
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Among 17 patients who continued 1-month escitalopram treatment was associated with significant increase in plasma anastrozole levels (24.5±2.3 ng/mL to 32.2±3.2 ng/mL, p29 kg/m2 ) patients (23.1±2.8 to 35.9±4.7 ng/mL, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: The purpose of the study was to evaluate the impact of escitalopram co-prescription on plasma anastrozole levels in post-menopausal breast cancer patients.
📊
Temel Bulgular & Veri:METHODS: A total of 24 post-menopausal operated breast cancer patients co-prescribed with escitalopram and anastrozole were included.
💡
Sonuç & Katkı:Among 17 patients who continued 1-month escitalopram treatment was associated with significant increase in plasma anastrozole levels (24.5±2.3 ng/mL to 32.2±3.2 ng/mL, p29 kg/m2 ) patients (23.1±2.8 to 35.9±4.7 ng/mL, p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: The purpose of the study was to evaluate the impact of escitalopram co-prescription on plasma anastrozole levels in post-menopausal breast cancer patients. METHODS: A total of 24 post-menopausal operated breast cancer patients co-prescribed with escitalopram and anastrozole were included. Blood samples were collected, before and 1-month after the onset of escitalopram to analyze plasma anastrozole and estradiol levels. RESULTS: No significant difference was noted in basal plasma anastrozole levels with respect to age, body mass index (BMI), tumor stage, previous antineoplastic treatments, concomitant medications, and serum estradiol levels. Overall, 17 patients completed the 1-month escitalopram treatment, while 7 patients discontinued escitalopram within the 1st week of the treatment. Basal anastrozole levels of 24 patients were 26.1±2.4 ng/mL. Among 17 patients who continued 1-month escitalopram treatment was associated with significant increase in plasma anastrozole levels (24.5±2.3 ng/mL to 32.2±3.2 ng/mL, p29 kg/m2 ) patients (23.1±2.8 to 35.9±4.7 ng/mL, p

🔖

Bu Makaleye Atıf Yap

ÖZYURT, H., ÖZDEN, S., GEMİCİ, C., ÜLER, P., YAPRAK, G., TEPETAM, H., KÜÇÜKİBRAHİMOĞLU, E., GÖREN, M. Z., ODABAŞ, H., NEŞETOĞLU, N., URAL, D., GÜMÜŞ, M. (2022). Escitalopram co-prescription in anastrozole-treated breast cancer patients. İstanbul Kuzey Klinikleri, Cilt: 9 - Sayı: 3, 248–255. https://ajindex.com/articles/551221

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Abubakar MB, Wei K, Gan SH. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenet Genomics 2014;24:575–81
  2. Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P. Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer 2008;15:27–36
  3. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc 2010;85:560–6
  4. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res 2009;69:66
  5. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53
  6. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004;:57–71
  7. Cvetković J, Nenadović M. Depression in breast cancer patients. Psychiatry Res 2016;240:343–7
  8. Deshields T, Tibbs T, Fan MY, Taylor M. Differences in patterns of depression after treatment for breast cancer. Psychooncology 2006;15:398–406
  9. Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jørgensen T. Depression as a prognostic factor for breast cancer mortality. Psychosomatics 2003;44:24–30
  10. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003;54:269–82
  11. Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:318–23
  12. Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology 2011;88:333–9
  13. Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, Eliasson E. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br J Clin Pharmacol 2010;69:411–7
  14. Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, et al. Augmentation of endoxifen exposure in tamoxifen-treated women follow